Intuitive Surgical Intrinsic Stock Value – INTUITIVE SURGICAL Reports Q4 FY2022 Earnings: Revenue Declines, Net Income Rises 6.7% Year-Over-Year

Earnings report

Intuitive Surgical Intrinsic Stock Value – On January 24th 2023, INTUITIVE SURGICAL ($NASDAQ:ISRG), a leading provider of robotic-assisted medical devices for minimally-invasive surgery, reported their earnings results for the fourth quarter of FY2022, ending December 31 2022. INTUITIVE SURGICAL is a publicly-traded company on the NASDAQ stock exchange and has seen steady growth over the years. The total revenue for the quarter was USD 324.9 million, a decrease of 14.6% compared to the same period last year. This was attributed to a decrease in system and instrument revenue and was in line with analysts’ expectations. The reported net income saw an increase of 6.7% to USD 1655.0 million year over year.

This increase was mainly driven by a reduction in operating expenses and cost of goods sold, partially offset by lower revenue. The guidance provided was in line with analysts’ estimates of USD 325 million. Overall, INTUITIVE SURGICAL reported their earnings results for the fourth quarter of FY2022, ending December 31 2022, meeting earnings expectations and providing guidance for FY2023 that was in line with analysts’ estimates. Despite a decline in total revenue year over year, INTUITIVE SURGICAL reported a 6.7% increase in net income year over year that can be attributed to a reduction in operating expenses and cost of goods sold.

Market Price

On Tuesday, INTUITIVE SURGICAL reported its fourth quarter earnings for FY2022. In spite of the revenue decline, INTUITIVE SURGICAL stock opened at $254.6 and closed at $258.0, up 0.8% from its last closing price of 256.0. Despite the pandemic’s negative impact on procedure volumes, the company’s net income rose due to cost saving initiatives and increased efficiency. The company also noted that it had seen an increase in demand for its robotic surgical systems and instruments throughout the quarter.

The company expects this trend to continue as it focuses on expanding its customer base and improving its product portfolio. The company’s stock performance indicated a bullish sentiment among investors, which is an encouraging sign for the company’s long-term outlook. With the launch of new products and services, INTUITIVE SURGICAL is well-positioned to capitalize on future growth opportunities. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Intuitive Surgical. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Intuitive Surgical. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Intuitive Surgical. More…

Key Ratios Snapshot

Some of the financial key ratios for Intuitive Surgical are shown below. More…

VI Analysis – Intuitive Surgical Intrinsic Stock Value

Intuitive Surgical is a company that has long-term potential according to its fundamentals, as determined by the VI app. This app has made it easier to analyze the company and comes to the conclusion that the fair value of its shares is around $298.6. However, the current price of Intuitive Surgical’s stock is $258.0, which is undervalued by 14%. Its products, such as da Vinci Surgical System and Ion Surgical System, are designed to provide surgeons with superior visualization, enhanced dexterity, greater precision and improved access during minimally invasive surgery. Intuitive Surgical is also well-positioned to benefit from the global trend towards minimally invasive surgery, which is expected to grow significantly in the coming years. This could boost its sales and profits, leading to further appreciation of the stock. The company has a strong balance sheet and a healthy cash position, enabling it to invest in research and development, acquisitions and other strategic initiatives. In conclusion, Intuitive Surgical is an attractive stock with long-term potential and a fair value of $298.6. As the stock is currently trading below its fair value at $258.0, it presents an opportunity for investors to buy at a discount. More…

VI Peers

The company’s da Vinci surgical system consists of a surgeon’s console, a patient-side cart and a vision system. The company’s competitors in the robotic surgery market include Stryker Corp, Medtronic PLC, Becton, Dickinson and Co.

– Stryker Corp ($NYSE:SYK)

With a market capitalization of $84.98 billion as of 2022, Stryker Corporation is one of the world’s leading medical technology companies. Headquartered in Kalamazoo, Michigan, the company offers a broad range of products and services in orthopedics, medical and surgical, and neurotechnology and spine that help improve patient care and quality of life. The company’s products include implants used in hip, knee and shoulder replacements, as well as instrumentation and software used in operating rooms and for patient rehabilitation. In addition, Stryker offers a wide range of products and services for minimally invasive surgery, including robotic-assisted surgery systems. The company’s return on equity was 10.79% as of 2022.

– Medtronic PLC ($NYSE:MDT)

Medtronic PLC is a medical technology company that develops and produces a variety of medical devices and software products. The company has a market capitalization of 112.31 billion as of 2022 and a return on equity of 7.49%. Medtronic PLC’s products are used in a wide range of medical procedures, including cardiovascular, neurological, and orthopedic procedures. The company’s products are sold in over 150 countries around the world.

– Becton, Dickinson and Co ($NYSE:BDX)

Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, laboratory equipment, and diagnostic products. The company has a market cap of 64.37B as of 2022 and a return on equity of 6.42%. The company’s products are used in a variety of medical procedures, including blood transfusions, IV start kits, and diabetes care.

Summary

INTUITIVE SURGICAL reported a decrease in total revenue of 14.6% year-over-year for the fourth quarter of FY2022. Nevertheless, the company’s net income saw an increase of 6.7%, showing that it was able to optimize its operations. These results demonstrate that INTUITIVE SURGICAL is a financially sound company and an attractive investment opportunity. The company’s strong financial performance indicates that it is well-positioned to benefit from growth in the medical device industry and capitalize on future opportunities. The innovative products they offer, such as robotic-assisted surgery, provide the potential to capture a larger market share and gain competitive advantage. Furthermore, INTUITIVE SURGICAL is investing in research and development which is likely to bring about further product innovation and growth opportunities. Investors should also be aware of the risks associated with investing in INTUITIVE SURGICAL. The company faces intense competition in the medical device industry, which could lead to lower market share and revenues.

Additionally, government regulations and reimbursement policies can have a negative impact on the company’s profitability. Its strong financial performance and potential for growth make it a worthwhile consideration for investors looking to capitalize on the medical device industry.